Antisoma im Griff der Bullen! - 500 Beiträge pro Seite

[GRILLER]

Bernecker wird sich warscheinlich vom hochhaus stürzen, wenn er eines tages sieht, wie antisoma bei 10 euro steht.

Dann wird er seine oma anbetteln und sagen er möchte sich unten im dorf beim wald und -wiesenhändler ein (neues auto") kaufen, in wirklichkeit wird er dann 3000 mark bei der sparkasse einzahlen und dann 75 Antisoma Aktien für 20 euro kaufen!

Ihr werdet es in allen zeitungen lesen!

[bigguru]

ich habe euch hier mal die produkte in der pipeline aufgelistet.sieht nicht schlecht aus. die aktie wird aber meiner meinung nach noch weiter fallen, schlimmstens bis auf 1,50!mit einem einstieg warte ich noch ab!

[boerseaugsburg]

hallo bigguru,

wie sind die changen auf eine zulassung für theragyn in % und wann wird die zulassung voraussichtlich kommen.

gruss ba

[bigguru]

Theragyn (pemtumomab) and ovarian cancer

pemtumomab comprises a murine monoclonal antibody capable of conjugation to the radioisotope Yttrium-90. The antibody is specific for PEM, a marker overexpressed on the surface of epithelial tumour cells including ovarian, gastric, pancreatic, colorectal, breast and lung. This product was originally developed by the ICRF whose scientists carried out a long-term Phase II study treating women with ovarian cancer, many with late-stage disease. This study identified a subgroup of 21 women out of 52 participants who were in remission at the time of treatment. We continue to follow the progress of these woman. As of 1 March 2000, 66% of the pemtumomab-treated women, with a median follow-up in excess of 8 years, were still alive.



Ovarian cancer is the second most common gynaecological cancer. Survival rates are poor because the majority of women present with advanced disease. Antisoma is developing pemtumomab as an additional treatment for ovarian cancer following initial surgery and chemotherapy. While technically these women may be in remission, with no detectable disease, a high proportion of them relapse. Treatment with a single intraperitoneal dose of pemtumomab is thought to target and destroy any cancer cells remaining after surgery and chemotherapy, thus preventing or delaying relapse.

Antisoma is now conducting a multi-centre, randomised prospective Phase III study. The SMART (Study of Monoclonal Antibody RadioimmunoTherapy) study is designed to demonstrate pemtumomab’s potential survival advantage for treated women and safety profile, and to provide data suitable for a registration submission in the US and Europe. The study will enrol 300 patients, half of whom will receive active treatment, and follow up is anticipated to average 2.5 years. The primary endpoint is survival, with secondary endpoints measuring time to relapse, quality of life, length and frequency of hospital stays, adverse events, etc. The study is being conducted in over 50 centres in North America, Europe and Australia.


Antisoma estimates that approximately 65% of new ovarian cancer cases and 20% of relapsed cases could be treated with pemtumomab in the key markets of North America, Europe and Japan. This represents a potential annual market size of 85,000 pemtumomab doses. This is a market potentially worth US$850 million per annum, if all eligible patients were treated.

In the US, companies can apply for registration of products that treat diseases affecting only limited patient numbers as ‘orphan drugs’, a classification that confers market exclusivity for up to seven years from first commercial sale. Antisoma has been granted orphan drug status in the US for pemtumomab in ovarian cancer. Similar legislation exists in other countries, including the recent addition of the European Union.

If you are resident in the US and would like more information about participating in the SMART study, please click here.



Theragyn (pemtumomab) in other indications

Results from studies to date treating ovarian cancer patients suggest that pemtumomab may be effective in treating the intra-abdominal spread of other epithelial cancers such as gastric, colorectal, uterine and pancreatic.

Antisoma is conducting a pilot Phase II study for pemtumomab with advanced gastric cancer patients. Worldwide, gastric cancer is the second most common cancer after lung cancer. Approximately 90% patients die within five years of diagnosis because the majority of tumours are not detected until they have spread. Antisoma estimates that there are over 100,000 advanced gastric cancer patients who could be treated with pemtumomab annually in North America, Europe and Japan.

As part of the development and commercialisation agreement signed during 1999, Abbott has rights to develop pemtumomab for other intra-abdominal indications including gastric, pancreatic, uterine and colorectal cancers. In the past year, Abbott has also agreed to support Antisoma’s ongoing pilot Phase II study in gastric cancer.








ich würde noch nicht einsteigen!die bios werden noch weiter fallen. biogen bringt am do. vor börsenbeginn zahlen. haltet puts bereit.................!

[NostradamusIII]

übrigens 500 % - nicht vergessen !!

[NostradamusIII]

wußtet ihr das jede 10 Frau eine Form des Brustkrebses oder einen Tumar oder was ähnliches har!

Antisoma kann heilen!

[NostradamusIII]

sollte natürlich Tumor sein...

[NostradamusIII]

armer Bernecker - kauf schnell !!

jetzt gehts los!

morgen kratzen wir an der 1 € Marke!